Pebrilzo Becomes Second FDA-Approved Perjeta Biosimilar for HER2-Positive Breast Cancer but Cannot Launch Before Third Quarter 2028
The FDA approved Biocon's Pebrilzo, a second Perjeta biosimilar for adults with HER2-positive breast cancer. It will not launch in the United States before the third quarter of 2028.
Medical Daily ·